NCT00693433: Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma |
|
|
| Completed | 1 | 15 | US | dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis | National Cancer Institute (NCI) | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma | 08/10 | | | |
NCT00398515: Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma |
|
|
| Completed | 1 | 25 | US | lenalidomide, CC-5013, IMiD-1, Revlimid, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma | 02/12 | | | |